The accuracy of tumor size measurement and clinical T staging for resected lung cancer: Retrospective analysis of 1 880 patients / 中国胸心血管外科临床杂志

@#Objective To elucidate the correlation between radiological tumor size (RTS) and pathological tumor size (PTS), and to evaluate the accuracy of clinical T staging. Methods Data on patients who underwent complete resection between September 2018 and June 2019 were retrospectively collected. The correlation between RTS and PTS was analyzed by and we assessed the agreement between clinical and pathologic T staging. Results Finally, 1 880 patients were included. There were 778 males and 1 102 females at average age of 57±11 years. In the entire cohort, the RTS and PTS was 19.1±13.5 mm and 17.7±14.0 mm, respectively (P<0.001). The RTS and PTS showed a strong linear correlation with the Pearson’s correlation coefficient calculated as 0.897. The mean RTS was significantly larger than PTS (P<0.001) in tumors≤3 cm, but significantly smaller in tumors>4 cm. The overall concordance rate between clinical and pathological T staging was 65.6%. Clinical staging failed to detect T4 disease in 29.4% (5/17) of patients. Male patients and the presence of cavities within nodules were independent significant factors leading to inaccurate clinical T staging. Conclusions The correlation between the tumor sizes measured on thin-section computed tomography and pathologic specimens varies with the real tumor size. Methods and techniques for improving clinical T staging accuracy is in urgent need.

Advances in indications of anatomical pulmonary segmentectomy for early-stage lung cancer / 中国胸心血管外科临床杂志

@#Whether anatomical segmentectomy can replace lobectomy in the treatment of early-stage lung cancer remains controversial. A large number of studies have been conducted for decades to explore whether pulmonary segmentectomy can treat early-stage lung cancer, which is actually to explore the indications of intentional segment-ectomy. With the development of scientific researches, it is found that many characteristics affect the malignancy of lung cancer, and the different grades of each characteristic affect the prognosis of patients. It is worth exploring whether different surgical approaches can be used for early-stage lung cancer with different characteristics and different grades. This article reviews the literature and studies to discuss the advances in indications of segmentectomy for early-stage lung in terms of tumor size, consolidation-to-tumor ratio, pathological classification and tumor location, respectively. The objective of this review is to help thoracic surgeons to objectively and scientifically select the surgical method according to the clinical characteristics of early-stage lung cancer.

Clinicopathologic analysis of micro and mini parotid gland tumors / 北京大学学报(医学版)

OBJECTIVE@#To investigate the clinicopathological characteristics of micro and mini parotid gland tumors and to provide reference for their clinical diagnosis and treatment.@*METHODS@#Patients with parotid gland tumors treated in the Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology from December 2012 to April 2020 were selected. Relevant clinical data of the patients with tumor diameter ≤20 mm detected by preoperative CT were collected to analyze the clinicopathological characteristics and prognosis of micro and mini parotid gland tumors. And the collected data were divided into two groups with diameter 11-20 mm and diameter ≤10 mm according to tumor diameter measured by preoperative CT. The clinicopathological differences between the two groups were statistically analyzed.@*RESULTS@#A total of 2 067 patients with primary epithelial parotid gland tumors were collected, and 685 patients with tumor diameter ≤20 mm were examined by CT, accounting for 33.1%. The ratio of male to female patients with micro and mini parotid gland tumors was 1 ∶1.93, the average age was (45.3±13.8) years (12-83 years), and the median course of disease was 12 months (1 week to 30 years). Among them, 635 cases (92.7%) were benign tumors, 50 cases (7.3%) were malignant tumors, and the ratio of benign to malignant was 12.7 ∶1. The most common benign tumor was pleomorphic adenoma, and the most common malignant tumor was mucoepidermoid carcinoma. The micro and mini parotid gland tumors were divided into 11-20 mm group (n=611) and ≤10 mm group (n=74), the clinical characteristics comparison of the two groups of gender ratio, average age, course of di-sease had no statistical difference (P>0.05). In the 11-20 mm diameter group, the percentage of benign and malignant tumor was 92.8% (567/611) and 7.2% (44/611) respectively, and the ratio of benign to malignant tumors was 12.9 ∶1. In the ≤10 mm diameter group, the percentage of benign and malignant tumor was 91.9% (68/74) and 8.1% (6/74) respectively, and the ratio of benign to malignant tumors was 11.3 ∶1. There was no significant difference between the two groups (P>0.05). Fifty patients with malignant tumor were followed up for the median follow-up period of 39.5 months (1-91 months). Local recurrence occurred in 2 patients with one death. The overall 2-year survival rate was 93.7% and the 5-year survival rate was 89.3%.@*CONCLUSION@#The majority of micro and mini parotid gland tumors was benign lesion. There was a good prognosis for micro and mini parotid gland carcinoma. Early surgical treatment was recommended for micro and mini parotid gland tumors.

Prognosis Analysis of Non-small Cell Lung Cancer with Diameter over 7.0 cm Based on SEER Database / 肿瘤防治研究

Objective To analyze the mortality risk and evaluate the curative effects of surgery and non-surgery on NSCLC with diameter > 7.0 cm. Methods We collected the data of NSCLC patients with diameter > 7.0 cm from 2010 to 2015 from the SEER database. The 1, 2, 3-year survival rates were analyzed by life table method. Overall survival curve was estimated by Kaplan-Meier method. Univariate and multivariate Cox regression models were used to analyze the independent prognostic factors. Results The 1, 2, 3-year survival rates were 51.8%, 33.0% and 25.0%, respectively. In univariate and multivariate analyses, tumor size, N stage and treatment were the independent prognostic factors (P < 0.001). Conclusion Surgery is benefited for the prognosis of stage N0-N1 NSCLC patients with diameter > 7.0 cm. And for stage N2 NSCLC patients with diameter 7.0-9.0 cm, surgical treatment has advantages in improving the prognosis. Surgical and non-surgical patients with tumor diameter ≥9.0 cm or lymph node N3 stage have no statistically significant differences in prognosis. In addition, palliative treatment does not improve the prognosis of patients.

Expression of replication factor C4 in pancreatic ductal adenocarcinoma and its correlation with prognosis / 国际生物医学工程杂志

Objective:To detect the expression of replication factor C4(RFC4) in pancreatic ductal adeno-carcinoma, and to explore the clinical prognosis of RFC4 and pancreatic ductal adenocarcinoma. To explore the possibility of RFC4 as a potential biomarker for pancreatic ductal adenocarcinoma.Methods:The mRNA level of RFC4 in pancreatic ductal adenocarcinoma and normal tissues adjacent to the cancer was analyzed by bioinformatics methods, and the relationship between its expression and the survival rate of patients with pancreatic ductal adenocarcinoma was analyzed. The clinicopathological data of 76 patients with pancreatic ductal adenocarcinoma who underwent surgical treatment were retrospectively analyzed. Immunohistochemical method was used to detect the expression level of RFC4 protein in pancreatic ductal adenocarcinoma tissue and normal tissues adjacent to the cancer, and to analyze its relationship with clinicopathological characteristics of patients with pancreatic ductal adenocarcinoma.Results:The results of bioinformatics analysis showed that RFC4 mRNA was significantly highly expressed in pancreatic ductal adenocarcinoma tissue, and was significantly correlated with the overall survival rate ( P=0.046) and disease-free survival rate ( P=0.042) of the patients. Immunohistochemical results showed that the expression of RFC4 in pancreatic ductal adenocarcinoma tissue was significantly higher than that in normal tissues adjacent to the cancer. The high expression of RFC4 in pancreatic ductal adenocarcinoma tissue was related to tumor size ( P=0.043), but not related to age, gender, and tumor grade (all P>0.05). Conclusions:RFC4 is highly expressed in pancreatic ductal adenocarcinoma tissues and indicates a poor prognosis, and its expression level is related to the tumor stage of pancreatic ductal adenocarcinoma. RFC4 may serve as a new prognostic predictor for pancreatic ductal adenocarcinoma.

Cáncer de mama T1a y T1b: factores pronósticos de compromiso axilar / Breast cancer T1a y T1b: Prognostic factors of axillary commitment

Objetivos Se analizaron 331 pacientes con tumores de mama de entre 0,1 y 1 cm tratados en la Unidad de Mastologia Clínica Breast, Hospital Italiano de La Plata, en el período de tiempo comprendido entre 2012 y 2017. Se estudiaron factores pronósticos (tamaño tumoral, edad, ivl, grado histológico, tipo y subtipo tumoral y Ki67) y su relación con el compromiso ganglionar, el cual se encontró presente en 42 casos (12,98%). Resultados El subtipo tumoral con mayor afectación axilar fue el tn seguido por los Luminal B. La edad y tamaño tumoral no arrojaron datos relevantes. La ivl y el Ki67 fueron las variables más significativas en relación con el compromiso axilar. Conclusiones Pudimos concluir que nos hallamos dentro de los valores estándares publicados tanto nacional como internacionalmente

Objective We analyzed 331 patients with breast tumors between 0.1 and 1 cm treated in the Breast-Italian Hospital La Plata Clinical Mastology Unit, in the period between 2012 and 2017. We studied prognostic factors (tumor size, age, ivl, histological grade, tumor type and subtype and Ki67) and its relationship with lymph node involvement, which was present in 42 cases (12.98%). Results The tumor subtype with the most axillary involvement was tn followed by Luminal B. Age and tumor size did not yield relevant data. The ivl and the Ki67 were the most significant variables in relation to the axillary commitment. Conclusions We were able to conclude that we are within the standard values published both nationally and internationally

Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: The purpose of this study was to investigate the non-inferiority of omitting radiotherapy (RT) after breast-conserving surgery (BCS) for hormone receptor (HR)‒positive T1N0 breast cancer in elderly women. MATERIALS AND METHODS: From 2004 to 2014, HR-positive T1N0 breast cancer patients aged 50 years or older and receiving BCS were retrieved from the Surveillance, Epidemiology, and End RESULTS: 18 database. After propensity score matching between the no-RT and RT groups, univariate and multivariate analyses were performed. Identified prognostic factors were used to stratify the risk groups. In each risk group, 10-year cancer-specific survival (CSS) rates were compared between the no-RT and RT groups. RESULTS: After propensity score matching, the numbers of patients in the no-RT and RT groups were both 18,586. For patients who satisfied both a tumor size of 1-10 mm and a tumor grade of 1-2, omitting RT did not decrease the CSS rate at any age group, ranging from ≥ 50 to ≥ 85 years; for patients aged ≥ 50 years, the 10-year CSS rates in the no-RT and RT groups were 97.2% and 96.8%, respectively (adjusted hazard ratio, 0.862; p=0.312). However, for patients with a tumor size of 11-20 mm or tumor grade of 3-4, RT significantly increased the CSS rate irrespective of age. CONCLUSION: RT after BCS for HR-positive T1N0 breast cancer in elderly women might be omitted without causing a decrease in the CSS rate, but only in patients who satisfy both a small tumor size (≤ 10 mm) and low tumor grade (1-2).

Automated breast ultrasound system for assessing tumor size and predicting T stage in breast cancer / 西安交通大学学报(医学版)

Objective: To compare the feasibility of automated breast volume scanner automated breast ultrasound system (ABUS) and the traditional ultrasound (US) in measuring breast cancer size so as to evaluate their value in predicting breast cancer T staging. Methods: We retrospectively recruited 60 women with breast cancer who had received US and ABUS. The maximal tumor diameter was measured as tumor size. Based on the actual postoperative tumor size in pathology, Bland-Altman analysis and intraclass correlation coefficient (ICC) were used to compare the values measured by US and ABUS. Then we made a preliminary study of the accuracy of US and ABUS in predicting breast cancer T staging. Results: The best absolute agreement was shown between US and ABUS in measuring tumor size. Moreover, ABUS showed better agreement with histology than US [average difference (-1.09±3.61)mm vs. (-1.57±4.99)mm] with a higher ICC (0.93 vs. 0.86), especially for tumors which were more than 2 cm. In addition, both US and ABUS could predict breast cancer T staging relatively accurately (82.1% vs. 87.5%). Conclusion: Both US and ABUS showed good agreement with pathology in measuring tumor size. ABUS even outperformed US in assessing tumor size for tumors beyond 2 cm. Therefore, ABUS can be considered as an alternative to US in T staging of breast cancer.

Elevada mortalidad por cáncer cérvico-uterino en mujeres jóvenes del área metropolitana de Buenos Aires / High mortality for cervical cancer in young women from the Metropolitan Area of Buenos Aires

El cáncer cérvico-uterino, fiel indicador de inequidad social, sigue siendo un grave problema de salud pública en la República Argentina. Se suele afirmar que su frecuencia en mujeres jóvenes es baja y que las más expuestas son aquellas mayores de 35 años. Sin embargo, como ginecólogos oncólogos, con frecuencia acompañamos a morir a mujeres jóvenes que no han tenido acceso a tamizaje ni a tratamiento oportuno y adecuado del cáncer invasor. Esto ha motivado el presente análisis de frecuencia y supervivencia del cáncer cérvico-uterino en el contexto demográfico de las mujeres asistidas en el hospital de referencia en cáncer ginecológico de Buenos Aires. De los 748 casos analizados retrospectivamente (2007-2011), el 84.0% (n = 627) residía en el Área Metropolitana de Buenos Aires y el 76.9% (n = 576) fue admitido en estadios loco-regionalmente avanzados. El 53.6% (n = 401) presentó un diámetro tumoral > 4 cm y el 24.2% (n = 181) > 6 cm. Las tasas más bajas de supervivencia se observaron en tumores > 6 cm y en el subgrupo etario < 35 años. Tanto el tamaño tumoral como la edad conservaron su valor pronóstico tras ser ajustados en el análisis multivariado. En el subgrupo < 35 años, el 48% (n = 70) murió durante los 5 años siguientes al diagnóstico y la probabilidad de sobrevivir otros 5 años fue < 50%. Estos resultados representan una alerta sanitaria sobre la situación de mujeres jóvenes con cáncer cérvico-uterino en el Área Metropolitana de Buenos Aires, la cual concentra casi un tercio de la población del país.

he cervical cancer, which is a reliable indicator of social inequality, remains a major public health issue in Argentina. It is generally accepted that its frequency among young women is low, being the most exposed those over 35 years old. Nevertheless, as gynecologic oncologists, we have been accompanying young patients to their death, mostly women with neither access to screening strategies nor timely or suitable treatment. Such a situation motivated the present analysis of our data on frequency, survival, and demography of cervical cancer collected at the referral cancer hospital of Buenos Aires City. Of 748 cases retrospectively assessed (2007-2011), 84.0% (n = 627) resided in the Metropolitan Area of Buenos Aires; 76.9% (n = 576) were admitted at a locoregionally advanced stage. Regarding tumor size, 53.6% (n = 401) had tumors > 4 cm diameter and 24.2% (n = 181) > 6 cm. The lowest rates of disease-free survival and cause-specific survival were observed for tumor sizes > 6 cm and the age subgroup < 35 years old. Both tumor size and age retained their prognostic value after multivariate analysis adjustment. When focusing in patients under 35 years old, 48% (n = 70) died within 5 years following diagnosis and their probability of surviving 5 years more was < 50%. These figures raise a public health alert on young women with cervical cancer living in the Metropolitan Area of Buenos Aires, which concentrates almost one third of the country population.

Impact of Nodule Size on Malignancy Risk Differs according to the Ultrasonography Pattern of Thyroid Nodules

OBJECTIVE: To test whether the impact of thyroid-nodule size on the malignancy risk differs according to the ultrasonography (US) patterns of nodules. MATERIALS AND METHODS: This study is a post hoc analysis using data from the Thyroid Imaging Reporting and Data System (TIRADS) multicenter retrospective study which included 2000 consecutive thyroid nodules (≥ 1 cm) with final diagnoses. A total of 2000 consecutive thyroid nodules from 1802 patients (1387 women and 613 men; mean age, 51.2 ± 12.2 years) were enrolled in this study. The malignancy risk of the nodules was assessed according to the nodule size and US patterns (Korean-TIRADS). RESULTS: Overall, the malignancy risk did not increase as nodules enlarged. In high-suspicion nodules, the malignancy rate had no association with nodule size (p = 0.467), whereas in intermediate- or low-suspicion nodules there was a trend toward an increasing malignancy risk as the nodule size increased (p = 0.004 and 0.002, respectively). The malignancy rate of large nodules (≥ 3 cm) was higher than that of small nodules (< 3 cm) in intermediate-suspicion nodules (40.3% vs. 22.6%, respectively; p = 0.001) and low-suspicion nodules (11.3% vs. 7.0%, respectively; p = 0.035). There was a trend toward a decreasing risk and proportion of papillary carcinoma and an increasing risk and proportion of follicular carcinoma or other malignant tumors as nodule size increased (p < 0.001, respectively). CONCLUSION: The impact of nodule size on the malignancy risk differed according to the US pattern. A large nodule size (≥ 3 cm) showed a higher malignancy risk than smaller nodules in intermediate- and low-suspicion nodules.

Serum ghrelin levels in papillary thyroid carcinoma

ABSTRACT Objective Ghrelin plays a role in several processes of cancer progression, and numerous cancer types express ghrelin and its receptor. We aimed to investigate serum levels of ghrelin in patients with papillary thyroid carcinoma (PTC) and its association with the prognostic factors in PTC. Materials and methods We enrolled 54 patients with thyroid cancer (7 male, 47 female) and 24 healthy controls (6 male, 18 female) in the study. We compared demographic, anthropometric, and biochemical data, and serum ghrelin levels between the groups. Serum ghrelin levels were measured using as enzyme-linked immunosorbent assay. Results Ghrelin levels were similar between the groups, but plasma ghrelin levels were significantly higher in tumors larger than 1 cm diameter compared with papillary microcarcinomas. Serum ghrelin levels also correlated with tumor size (r = 0.499; p < 0.001). Body mass index, thyroid-stimulating hormone, and HOMA-IR levels were similar between the groups. There were no statistically significant differences regarding average age and other prognostic parameters including lymph node invasion, capsule invasion, multifocality and surgical border invasion between patients with microcarcinoma and tumors larger than 1 cm. Conclusion In our study, no significant difference in serum ghrelin levels was determined between patients with papillary thyroid cancer and healthy controls however, serum ghrelin levels were higher in tumors larger than 1 cm compared to in those with thyroid papillary microcarcinoma.

Consistency of tumor sizes measured by sonographic and pathological examination in papillary thyroid carcinoma / 中国耳鼻咽喉头颈外科

OBJECTIVE The aim of the study was to evaluated the difference and consistency in tumor size measured by sonographic and pathological examination in papillary thyroid carcinoma(PTC).METHODS A total of 114 patients with PTC, including 122 malignant nodules, was collected from Hangzhou First People's Hospital between Jun 2012 and Jun 2014. The tumor sizes were measured by preoperative sonographic and postoperative pathologic evaluation. Pearson correlation analysis, paired t-test, and Bland-Altman plot were used to evaluate the correlation and consistency in tumor size measured by the two methods.RESULTS Pearson correlation analysis showed that the largest tumor size measured by sonography were positively correlated with pathologic size (r=0.957, P=0.000). Paired t-test showed that there were statistically difference between sonographic size and pathological size (8.24±5.06) mmvs (7.79±4.75) mm,P=0.001. The absolute difference value of the largest tumor size measured by the two methods was from zero to 6.5 mm, with the average of (1.03±1.14) mm. Bland-Altman analysis showed that the limits of agreement (LoA) of difference was from -2.41 mm to 3.33 mm, with the 95% confidence interval from -2.87 mm to 3.78 mm.Within the limit of the consistency, the maximum moduli was 2.9 mm.CONCLUSION There is a significant discrepancy between the preoperative sonographic and the pathologic size of the papillary thyroid carcinoma, which should be taken into account in clinical practice.

An imputation-based method to reduce bias in model parameter estimates due to non-random censoring in oncology trials

In oncology trials, patients are withdrawn from study at the time when progressive disease (PD) is diagnosed, which is defined as 20% increase of tumor size from the minimum. Such informative censoring can lead to biased parameter estimates when nonlinear mixed effects models are fitted using NONMEM. In this work, we investigated how empirical Bayes estimates (EBE) could be exploited to impute missing tumor size observations and partially correct biases in the parameter estimates. 50 simulated datasets, each consisting of 100 patients, were generated based on the published model. From the simulated dataset, censoring due to PD diagnosis has been implemented. Using the post-hoc EBEs acquired from fitting the censored datasets using NONMEM, imputed values were generated from the tumor size model. Model fitting was carried out using censored and imputed datasets. Parameter estimates using both datasets were compared with true values. Tumor growth rate and cell kill rate were approximately 28% and 16% underestimated when fitted using the censored dataset, respectively. With the imputed datasets, relative biases of tumor growth rate and cell kill rate decreased to about 6% and 0%, respectively. Our work demonstrates that using EBEs acquired from fitting the model to the censored dataset and imputing the unknown tumor size observations with individual predictions beyond the PD time point is a viable option to solve the bias associated with structural parameter estimates. This approach, however, would not be helpful in getting better estimates of variance parameters.

The correlation between lesion size and contrast-enhanced ultrasound in breast cancer / 中华超声影像学杂志

Objective To investigate whether there are differences of the characteristics of the contrast‐enhanced ultrasound among breast cancer vary in size .Methods The contrast‐enhanced ultrasound perfusion mode were retrospectively analyzed in 113 cases of breast cancer patients with 119 lesions .They were divided into two groups according to the maximum diameter of the lesion based on ultrasound measured ,one group (≤2 0. cm ) 47 cases ,the other group (> 2 0. cm ) 72 cases .The characteristics and mode of contrast‐enhanced ultrasound of the lesion were analyzed ,including whether is greater than the two‐dimensional ultrasound in enhanced range ,enhanced strength ,the distribution of the contrast agent ,contrast agent perfusion sequence in lesions ,contrast mode ,and the existence of perforator vessels and perfusion defects .Results Enhanced strength ,the existence of perforator vessels and perfusion defects associated with the size of the lesions .The breast cancer lesions more than 20 cm were apt to higher enhance strength ,the presence of perfusion defects ,perforator vessels ( P 0 0.5) .Regardless of breast lesions size ,the enhanced range tended to larger than two‐dimensional ultrasound range ,and contrast‐enhanced ultrasound present inhomogeneous ,centrality and integrity filling and perfusion mode of quickly rising and falling .Conclusions Within breast tumor angiogenesis is gradual .With the increase of tumor volume ,more significant vascular heterogeneity ,breast cancer lesion are more prone to uneven high perfusion ,accompanied by perfusion defects and perforating vessels ,but the main sign of differentiating benign and malignant showed consistency between different sized lumps in breast cancer ,which included whether or not contrast mode and enhanced range greater than two‐dimensional ultrasonic range .

Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma

BACKGROUND/AIMS: The predictive role of contrast-enhanced ultrasonography (CEUS) before performing transarterial chemoembolization (TACE) has not been determined. We assessed the possible predictive factors of CEUS for the response to TACE. METHODS: Seventeen patients with 18 hepatocellular carcinoma (HCC) underwent TACE. All of the tumors were studied with CEUS before TACE using a second-generation ultrasound contrast agent (SonoVue(R), Bracco, Milan, Italy). The tumor response to TACE was classified with a score between 1 and 4 according to the remaining enhancing-tumor percentage based on modified response evaluation criteria in solid tumors (mRECIST): 1, enhancing tumor or =75%). A score of 1 was defined as a "good response" to TACE. The predictive factors for the response to TACE were evaluated during CEUS based on the maximum tumor diameter, initial arterial enhancing time, arterial enhancing duration, intensity of arterial enhancement, presence of a hypoenhanced pattern, and the feeding artery to the tumor. RESULTS: The median tumor size was 3.1 cm. The distribution of tumor response scores after TACE in all tumors was as follows: 1, n=11; 2, n=4; 3, n=2; and 4, n=1. Fifteen tumors showed feeding arteries. The presence of a feeding artery and the tumor size (< or =5 cm) were the predictive factors for a good response (P=0.043 and P=0.047, respectively). CONCLUSIONS: The presence of a feeding artery and a tumor size of less than 5 cm were the predictive factors for a good response of HCC to TACE on CEUS.

Can One Predict the Incidence of Metastasis in Oral Squamous Cell Carcinoma Patients Using Tumor Thickness.

Aim: The present study was undertaken with the purpose to assess the correlation between the presence of lymph node metastases and the size of tumor and the thickness of the tumor mass. Methods: The study included 80 consecutive cases of oral squamous cell carcinoma, who underwent radical neck dissection. The various level of lymph nodes in these cases were checked for metastases, which was then correlated with the size of tumor and the thickness of the tumor. Results: In this study it was revealed that there is a statistically non-significant (p = 0.3204) correlation between size of the tumor and regional cervical lymph node metastases, but a significant correlation (p = 0.0148) between thickness of the tumor and regional cervical lymph node metastases was observed. Conclusion: Thus we conclude that the tumor thickness was more in cases with skip metastasis than in cases without skip metastasis and tumors greater than 10mm in thickness have more chances of regional metastases.

The preoperative assessment of tumor size in breast ductal carcinomain situ:a comparative study between mammography and ultrasonography / 实用放射学杂志

Objective To compare the accuracy of mammography and ultrasonography in evaluating the tumor size of breast ductal carcinoma in situ before operation.Methods Eighty-seven patients with breast ductal carcinoma in situ confirmed by surgery pathology were retrospectively analyzed.All of the mammography and ultrasonography data were well-documented.The maximum diameter of the tumor was measured by mammography,ultrasonography and pathology,respectively.It was considered concordant if the difference between the imaging size and pathologic size was less than 0.5 cm.Pearson correlation analysis was used to determine the relation of imaging size with pathologic size.Results The range of the maximum diameter of the tumors measured by pathology,mammography and ultrasonography was 0.4-7.0 cm,0.8-6.9 cm and 0.5-4.8 cm,respectively.The mean value was (2.4±1.3)cm,(2.6±1.2)cm and (2.3±1.0)cm,respectively.The coefficient correlation between mammographic and pathologic size was 0.724,and between ultra-sonographic and pathologic size was 0.532.Conclusion Mammography is more accurate than ultrasonography in size assessment of breast ductal carcinoma in situ.

Riesgo de malignidad en masas renales sólidas menores a cuatro centímetros / Risk of malignancy in solid renal masses less than four centimeters

El tratamiento de las masas renales sólidas menores de cuatro centímetros constituye un tema de debate. La “vigilancia activa” se ha propuesto como alternativa para su manejo, sin embargo, estudios publicados recientemente, señalan que un porcentaje no despreciable de estos tumores resultan ser malignos, e incluso en un 6 por ciento de los casos pueden producir metástasis. El objetivo del presente estudio consiste en determinar el riesgo de malignidad en masas renales sólidas menores de cuatro centímetros en un grupo de pacientes sometidos a Nefrectomía Parcial Laparoscópica (NPL). Estudio retrospectivo de pacientes sometidos a NPL. Se seleccionaron aquellos que presentaron lesiones renales sólidas menores a 4 cm informadas por TAC y/o RMN. Se crearon intervalos de tamaño (<2 cm, 2-2.9 cm, 3-4 cm). Se realizó un análisis univariado para determinar el riesgo de malignidad de acuerdo al tamaño del tumor, estableciendo el Odds Ratio correspondiente y el intervalo de confianza (95 por ciento). Los datos obtenidos fueron analizados mediante el programa SPSS v17. Se consideró como significativo un p< 0.05. Entre los años 2000 y 2012 se efectuaron 135 nefrectomías parciales laparoscópicas por la presencia de una masa renal sólida. Noventa y dos casos presentaron lesiones menores a cuatro centímetros, los que fueron incluidos en este estudio. Del total de tumores el 9.8% resultó ser benigno en el estudio histopatológico definitivo. No existieron diferencias significativas (p=0,67) con respecto a la media del tamaño (2,2 y 2,57 cm respectivamente) entre los tumores benignos y malignos. El porcentaje de tumores malignos aumentó significativamente (p = 0,025) en las masas mayores de 2 cm, al compararlo con aquellas de menor tamaño (69 por ciento v/s 86.7 por ciento). Mediante el análisis univariado se estableció que el riesgo de malignidad se incrementa 4.9 veces (p=0.027) en aquellas masas renales sólidas mayores de 2 cm...

The treatment of solid renal masses less than four centimeters (cm) is a subject of debate. Active surveillance has been proposed as a management option, however, recently published studies indicate that, in a substantial proportion, these tumors are malignant; and even at 6 percent of the cases can produce metastases. The aim of this study was to determine the malignancy risk in solid renal masses less than four cm in a group of patients undergoing laparoscopic partial nephrectomy (LPN).A retrospective study of patients undergoing LPN was performed. We selected those who had solid renal lesions smaller than 4 cm reported by CT and/or MRI. Size ranges were set (<2 cm, 2-2.9 cm, 3-4 cm). Univariate analysis was performed to determine the risk of malignancy according to tumor size, obtaining the corresponding odds ratio and confidence interval (95 percent). Data were analyzed using SPSS v17. P-value < 0.05 was considered stadistically significant. RESULTS: One hundred and thirty five laparoscopic partial nephrectomies were performed due to a solid renal mass between 2000 and 2012. Of them, ninety-two cases had a lesion less than four cm, which were included in this study. From the total of tumors, 9.8 por ciento were proved benign on final histopathology. No significant difference was found between benign and malignant tumors when mean sizes were compared (2.2 and 2.57 cm, respectively, p =0.67). The percentage of malignant tumors was significantly higher in masses larger than 2 cm, compared with those of smaller size (86.7 percent v/s 69 percent respectively, p=0.025). Univariate analysis established that the malignancy risk is increased 4.9 times in solid renal masses larger than 2 cm (p = 0.027). Our study shows that although the risk of cancer increases significantly in renal masses from the 2 cm there is a considerable percentage of malignancy in masses below this size.

Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters.

CONTEXT: Vimentin is a mesenchymal marker, known to express in some epithelial carcinomas. AIMS: 1. To find out the expression of vimentin in infiltrating ductal carcinoma of breast (not otherwise specified), 2. To find out the correlation between expression of vimentin and prognostic markers such as tumor size, tumor grade, lymph node status, proliferation index (measured by Ki 67), and Nottingham prognostic index (NPI). MATERIALS AND METHODS: Study was done at Department of Pathology; 50 cases of infiltrating ductal carcinoma (NOS) were studied for tumor grade; immunohistochemistry was done using antibodies against vimentin and Ki 67. Percentages of positive cells were documented. An immunoscore was also calculated for vimentin. Vimentin expression was correlated with tumor size, lymph node status, Nottingham prognostic index, and Ki 67. Statistical analysis used: statistical correlation was done using Pearson’s chi-square test. A P value less than 0.01 was considered significant. RESULTS: Vimentin expression was seen in 18% of cases. Its expression correlated with high tumor grade and high growth fraction (P value < 0.01). It did not correlate with lymph node status, tumor size, and NPI. CONCLUSIONS: Increased vimentin expression is associated with bad prognostic factors. Immunohistochemistry with vimentin may be helpful in knowing the prognosis in cases of infiltrating ductal carcinoma of breast (NOS).

Prediction of Risk of Malignancy of Gastrointestinal Stromal Tumors by Endoscopic Ultrasonography

BACKGROUND/AIMS: The accurate preoperative prediction of the risk of malignancy of gastrointestinal stromal tumors (GISTs) is difficult. The aim of this study was to determine whether tumor size and endoscopic ultrasonography (EUS) features can preoperatively predict the risk of malignancy of medium-sized gastric GISTs. METHODS: Surgically resected, 2 to 5 cm gastric GIST patients were enrolled and retrospectively reviewed. EUS features, such as heterogeneity, hyperechoic foci, calcification, cystic change, hypoechoic foci, lobulation, and ulceration, were evaluated. Tumors were grouped in 1 cm intervals. The correlations of tumor size or EUS features with the risk of malignancy were evaluated. RESULTS: A total of 75 patients were enrolled. The mean tumor size was 3.43+/-0.92 cm. Regarding the risk of malignancy, 51 tumors (68%) had a very low risk, and 24 tumors (32%) had a moderate risk. When the tumors were divided into three groups in 1 cm intervals, the proportions of tumors with a moderate risk were not different between the groups. The preoperative EUS features also did not differ between the very low risk and the moderate risk groups. CONCLUSIONS: Tumor size and EUS features cannot be used to preoperatively predict the risk of malignancy of medium-sized gastric GISTs. A preoperative diagnostic modality for predicting risk of malignancy is necessary to prevent the overtreatment of GISTs with a low risk of malignancy.